Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Pantry Pride is paying $100 mil. in cash for Adams Drug to move into drug retailing and the Northeast. The supermarket chain currently operates 100 food units in the Southeast and 84 recently added home improvement centers in 27 states. The home centers were purchased in May via acquisition of New York-based Devon Home Center Stores. The acquisition of Adams allows Pantry Pride to try its hand at drug retailing in a region that is relatively well insulated from competition by the large natl. chains. Adams operates 420 drug and health and beauty aid stores in 10 Northeastern states. The chain is phasing out its smaller health and beauty aid stores in favor of a focus on larger stores with pharmacy departments. Under the agreement, Pantry Pride will pay $100 mil. to purchase Adams at a cash price of $24.39 per share. The acquisition is subject to a minimum tender of $80% of the company's 4.1 mil. shares of outstanding stock. Approximately 70% of Adams stock is owned by the Salmanson family, which has agreed to tender its shares to Pantry Pride. The drug chain's current management will remain in charge of operations. At $100 mil., Pantry Pride is offering about .3 times estimated 1984 sales of Adams and about 13 times estimated 1984 earnings of $7.4 mil. By comparison, Imasco paid .4 times previous year's sales and 23 times earnings for the larger Peoples purchase last March.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts